Chemokines in islet allograft rejection

被引:39
作者
Abdi, R
Means, TK
Luster, AD
机构
[1] Brigham & Womens Hosp, Div Renal, Lab Immunogenet & Transplantat, Boston, MA 02115 USA
[2] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Immunol & Inflammatory Dis, Boston, MA 02115 USA
[3] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA
[4] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pulm & Crit Care Unit, Boston, MA 02115 USA
关键词
islet allograft rejection; chemokine receptor 5; Th2; response; organ specificity of chemokines;
D O I
10.1002/dmrr.362
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chemokines have emerged as important regulators in the development, differentiation, and anatomic distribution of leukocytes. Studies of renal and cardiac allograft biopsies have revealed that the expression of many chemokine receptors and their ligands was associated with acute allograft rejection. However, the importance of these chemokine receptor systems varies in the host response to a particular allograft. In this regard, CXCR3 appears to play a more important role in cardiac allograft rejection than CCR2 and CCR5. We have found that CCR2, CCR5, and CXCR3 and their ligands, as well as Th1 cytokines are induced to high levels in rejecting islet allografts. Interestingly, targeting CCR5 resulted in a significant prolongation of islet allograft survival. This prolongation was associated with a Th2 response. Our data indicate that in the process of acute rejection, the temporal expression and the ultimate function of a given chemokine vary among different organs or tissues. Hence, each organ or tissue may require a unique set of chemokines to generate acute rejection. Targeting the appropriate chemokine receptors may provide a clinically useful strategy to prevent islet allograft rejection. Copyright (C) 2003 John Wiley Sons, Ltd.
引用
收藏
页码:186 / 190
页数:5
相关论文
共 24 条
  • [1] Abdi R, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133754
  • [2] The role of CC chemokine receptor 5 (CCR5) in islet allograft rejection
    Abdi, R
    Smith, RN
    Makhlouf, L
    Najafian, N
    Luster, AD
    Auchincloss, H
    Sayegh, MH
    [J]. DIABETES, 2002, 51 (08) : 2489 - 2495
  • [3] Chemokines and leukocyte traffic
    Baggiolini, M
    [J]. NATURE, 1998, 392 (6676) : 565 - 568
  • [4] Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis
    Boring, L
    Gosling, J
    Cleary, M
    Charo, IF
    [J]. NATURE, 1998, 394 (6696) : 894 - 897
  • [5] Cutting edge: Hierarchy of chemokine receptor and TCR signals regulating T cell migration and proliferation
    Bromley, SK
    Peterson, DA
    Gunn, MD
    Dustin, ML
    [J]. JOURNAL OF IMMUNOLOGY, 2000, 165 (01) : 15 - 19
  • [6] Low-molecular-weight heparins inhibit CCL21-induced T cell adhesion and migration
    Christopherson, KW
    Campbell, JJ
    Travers, JB
    Hromas, RA
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 302 (01) : 290 - 295
  • [7] Beneficial effects of targeting CCR5 in allograft recipients
    Gao, W
    Faia, KL
    Csizmadia, V
    Smiley, ST
    Soler, D
    King, JA
    Danoff, TM
    Hancock, WW
    [J]. TRANSPLANTATION, 2001, 72 (07) : 1199 - 1205
  • [8] Gerber SI, 1997, GLYCOBIOLOGY, V7, P11
  • [9] Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection:: blocking monocyte arrest and recruitment
    Gröne, HJ
    Weber, C
    Weber, KSC
    Gröne, EF
    Rabelink, T
    Klier, CM
    Wells, TNC
    Proudfoot, AE
    Schlöndorff, D
    Nelson, PJ
    [J]. FASEB JOURNAL, 1999, 13 (11) : 1371 - 1383
  • [10] Association of CCR5 del32 with reduced risk of asthma
    Hall, IP
    Wheatley, A
    Christie, G
    McDougall, C
    Hubbard, R
    Helms, PJ
    [J]. LANCET, 1999, 354 (9186) : 1264 - 1265